



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Rüdiger Klapdor

✉ Klapdor.Ruediger@mh-hannover.de;

✉ Ruediger.Klapdor@immanuelalbertinen.de

Michael Alexander Morgan

✉ Morgan.Michael@mh-hannover.de

Axel Schambach

✉ Schambach.Axel@mh-hannover.de

[†]These authors have contributed
equally to this work and share
first authorship

[‡]These authors share senior authorship

RECEIVED 05 February 2025

ACCEPTED 06 February 2025

PUBLISHED 21 February 2025

CITATION

Kutle I, Polten R, Stalp JL, Hachenberg J,
Todzey F, Hass R, Zimmermann K,
von der Ohe J, von Kaisenberg C,
Neubert L, Kamp JC, Schaudien D,
Seyda A-K, Hillemanns P, Klapdor R,
Morgan MA and Schambach A (2025)
Corrigendum: Anti-Mesothelin
CAR-NK cells as a novel targeted
therapy against cervical cancer.
Front. Immunol. 16:1571555.
doi: 10.3389/fimmu.2025.1571555

COPYRIGHT

© 2025 Kutle, Polten, Stalp, Hachenberg,
Todzey, Hass, Zimmermann,
von der Ohe, von Kaisenberg, Neubert, Kamp,
Schaudien, Seyda, Hillemanns, Klapdor, Morgan
and Schambach. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer

Ivana Kutle^{1†}, Robert Polten^{1†}, Jan Lennart Stalp^{1,2},
Jens Hachenberg^{1,2}, Felix Todzey¹, Ralf Hass²,
Katharina Zimmermann¹, Juliane von der Ohe²,
Constantin von Kaisenberg², Lavinia Neubert^{3,4}, Jan C. Kamp^{4,5},
Dirk Schaudien⁶, Ann-Kathrin Seyda¹, Peter Hillemanns²,
Rüdiger Klapdor^{1,2,7*‡}, Michael Alexander Morgan^{1*‡}
and Axel Schambach^{1,8*‡}

¹Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany, ²Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany, ³Institute of Pathology, Hannover Medical School, Hannover, Germany, ⁴Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover, Germany, ⁵Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany, ⁶Fraunhofer Institute for Toxicology and Experimental Medicine, ITEM, Hannover, Germany, ⁷Department of Gynecology and Obstetrics, Albertinen Hospital Hamburg, Hamburg, Germany, ⁸Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, United States

KEYWORDS

cervical cancer, immunotherapy, chimeric antigen receptor (CAR), CAR-NK cells, Mesothelin, chemotherapy, CAR-T cells

A Corrigendum on

Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer

By Kutle I, Polten R, Stalp JL, Hachenberg J, Todzey F, Hass R, Zimmermann K, von der Ohe J, von Kaisenberg C, Neubert L, Kamp JC, Schaudien D, Seyda A-K, Hillemanns P, Klapdor R, Morgan MA and Schambach A (2024) *Front. Immunol.* 15:1485461. doi: 10.3389/fimmu.2024.1485461

In the published article, there was an error in **Supplementary Figure 8**. The graphical data shown in **Supplementary Figure 8** was inadvertently duplicated, so that the same data is displayed twice in the figure. This error was present only in the submitted PDF version of the **Supplementary Material**, while the individually submitted figure files were correct. It appears that an intended edit was not properly incorporated into the final compiled PDF that was uploaded during submission, leading to this unintended duplication.

The correct **Supplementary Figure 8** appears below.

“**Supplementary Figure 8** Comparison of 2nd and 3rd generation CARs. Live cell imaging-based cytotoxicity assays of anti-Mesothelin CAR-NK-92 cells against mCherry⁺

SiHa cells. CAR-NK-92 cells were co-cultured with mCherry⁺ SiHa cells for 72 hours in a 96-well plate at 1:1 (**A**) and 1:16 (**B**) effector to target (E:T) ratios. The anti-tumor activity of the different generations of anti-Mesothelin CAR-NK-92 cells was determined by monitoring the changes in the red-surface area over 72 hours. Data are displayed as mean \pm SD, n=3-4, conducted in technical triplicates. Statistical analysis was performed using two-way ANOVA for comparison of 28- BB ζ : 3rd generation anti-Mesothelin CAR-NK-92 cells (CD28-41BB-CD3 ζ) to BB ζ : 2nd generation (41BB-CD3 ζ) and 28 ζ : 2nd generation (CD28-CD3 ζ) anti-Mesothelin CAR-NK-92 cells at 24, 48 and 72 hours. Non-significant differences are indicated as ns.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The supplementary material has been updated within the original article.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.